EUVIMEDEUVIMED entdecken
Open Access

Identification of urinary metabolic biomarkers for histone 3 lysine27-to-methionine mutation diagnosis in brainstem gliomas

Xiaoou Li, Wei Sun iD, Zhengguang Guo, Feng Qi, Tian Li, Yujin Wang, Mingxin Zhang, Aiwei Wang, Zhuang Jiang, Luyang Xie, Yiying Mai, Yi Wang und 4 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Xiaoou Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Histones, Brain Stem Neoplasms, Glioma, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Beijing Municipal Public Welfare Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brainstem gliomas (BSGs) harboring a histone 3 lysine27-to-methionine (H3K27M) mutation represent one of the deadliest brain tumors with a dismal prognosis, as they exhibit a much worse response to therapy compared to the wildtype BSGs. Early noninvasive recognition of the H3K27M mutation is paramount for clinical decision-making in treating BSGs.

Methods

Plasma and urine samples were prospectively collected from BSG patients before biopsy or surgical resection and were chronologically divided into discovery, test, and validation cohorts. Utilizing the discovery and test cohort samples, an untargeted metabolomic strategy was exploited to identify candidate metabolite biomarkers, related to the H3K27M mutation. The candidate biomarkers were validated in the validation cohort with a targeted metabolomic method.

Results

Differential metabolomic profiles were detected between the H3K27M-mutant and wild-type BSGs in both the plasma and urine, the metabolomic changes were more dramatic in urine than in plasma. After rigorous screening for candidate biomarkers and validation with a targeted metabolomic approach, 3 metabolites, nomilin, Lys–Leu, and Hawkinsin, emerged as significantly elevated biomarkers in H3K27M-mutant BSG urine samples. The biomarker panel combining the 3 metabolites had a diagnostic area under the curve (AUC) of approximately 75%. Furthermore, the biomarker panel improved the prediction accuracy of radiomics/clinical models to an AUC value as high as 93.38%.

Conclusions

A urinary metabolite biomarker panel that exhibited high accuracy for noninvasive prediction of the H3K27M mutation status in BSG patients was identified. This panel has the potential to improve the predictive performance of current radiomics models or clinical features.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HistonesBrain Stem NeoplasmsGliomaBiomarkers, TumorMutationHumansMaleFemaleMiddle AgedAdultFollow-Up StudiesPrognosisMethionineMetabolomicsLysineProspective StudiesYoung AdultAged

Stichwörter der Autor:innen

BSGsH3K27Mbrainstem gliomasmetabolomicsurine

Substanzen

HistonesBiomarkers, TumorMethionineLysine

Autor:innen und Institutionen

  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Proteomics Center, Core Facility of Instrument, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
  • Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Wei Sun, Liwei Zhang

Förderung

  • Beijing Municipal Public Welfare Development

Zitieren

APA

Li, X., Sun, W., Guo, Z., Qi, F., Li, T., Wang, Y., Zhang, M., Wang, A., Jiang, Z., Xie, L., Mai, Y., Wang, Y., Wu, Z., Ji, N., Zhang, Y., & Zhang, L. (2025). Identification of urinary metabolic biomarkers for histone 3 lysine27-to-methionine mutation diagnosis in brainstem gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf038

Vancouver

Li X, Sun W, Guo Z, Qi F, Li T, Wang Y, et al. Identification of urinary metabolic biomarkers for histone 3 lysine27-to-methionine mutation diagnosis in brainstem gliomas. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf038

BibTeX
@article{Li2025,
  author = {Li, Xiaoou and Sun, Wei and Guo, Zhengguang and Qi, Feng and Li, Tian and Wang, Yujin and Zhang, Mingxin and Wang, Aiwei and Jiang, Zhuang and Xie, Luyang and Mai, Yiying and Wang, Yi and Wu, Zhen and Ji, Nan and Zhang, Yang and Zhang, Liwei},
  title = {Identification of urinary metabolic biomarkers for histone 3 lysine27-to-methionine mutation diagnosis in brainstem gliomas},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf038}
}
Kostenlos starten →